Cardiovascular Prevention for Persons With HIV

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection. Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces risk for heart disease in persons who are at increased risk (such as the case with HIV infection).

Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure medication (or a placebo), and will be seen at 3 study visits over 4 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Understanding the Increased Risk of Cardiovascular Disease in People With HIV

NCT00577681

HIV Infections

COMPLETED

Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications

NCT00796822

HIV Cardiovascular Diseases Atherosclerosis

COMPLETED PHASE2

Cardiovascular Diseases in HIV-infected Subjects (HIV-HEART Study)

NCT01119729

Detection of Frequency, Severity and Progression of Cardiovascular Diseases in Patients With HIV-infection. Effect on Cardiovascular Risk and Life Quality by Age, Gender, Classic Cardiovascular Risk Factors, HIV-specific Cardiovascular Risk Factors, Cardiovascular Medication, Antiretroviral Medication

COMPLETED

Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People

NCT00864916

HIV Vascular Diseases Cardiovascular Diseases +2 more

COMPLETED PHASE2

HIV Treatment and CVD Events

NCT01054638

HIV Infection Cardiovascular Disease Infection, Human Immunodeficiency Virus +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection Cardiovascular Disease Risk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lisinopril

Lisinopril 10mg once daily

Group Type EXPERIMENTAL

Lisinopril

Intervention Type DRUG

Participants randomized to take lisinopril (active) or matching placebo pill once daily

Lisinopril Placebo

Placebo pill (matched to lisinopril) once daily

Group Type PLACEBO_COMPARATOR

Lisinopril

Intervention Type DRUG

Participants randomized to take lisinopril (active) or matching placebo pill once daily

Pravastatin

Pravastatin 20mg once daily

Group Type EXPERIMENTAL

Pravastatin

Intervention Type DRUG

Participants randomized to take pravastatin (active) or matching placebo pill once daily

Pravastatin placebo

Placebo pill (matched to pravastatin) once daily

Group Type PLACEBO_COMPARATOR

Pravastatin

Intervention Type DRUG

Participants randomized to take pravastatin (active) or matching placebo pill once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pravastatin

Participants randomized to take pravastatin (active) or matching placebo pill once daily

Intervention Type DRUG

Lisinopril

Participants randomized to take lisinopril (active) or matching placebo pill once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV Infection with viral load 'undetectable' while taking antiretroviral therapy
* Age ≥40
* Framingham risk score (FRS) ≥5%, or ≥3% with ≥5 years of exposure to antiretroviral therapy

Exclusion Criteria

* Known cardiovascular disease or Framingham risk score (FRS) ≥20%
* Blood pressure ≥140/90
* LDL cholesterol ≥160 (with FRS \<10%), or ≥130 (with FRS 10-20%)
* Currently taking, or has a medication contraindication to take, a 'statin', an ACE inhibitor, or an angiotensin receptor blocker medication
* Cirrhosis or plasma ALT/AST levels \>2x upper limit of normal
* Chronic kidney disease and a creatinine \>2.0mg/dL
* Triglycerides \>500mg/dL

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No